Inhibition of Rhinovirus Replication in Organ Culture by a Potential Antiviral Drug

Abstract

The compound 2-amino-1-(isopropyl sulfonyl)-6-benzimidazole phenyl ketone oxime (LY122771-72) at a concentration of 0.2 microgram/ml completely inhibited rhinovirus replication in human embryonic nasal organ cultures, although in the absence of virus the compound did not inhibit ciliary activity when used at a concentration of 25 micrograms/ml. When added 26 hr after infection, the compound stopped rhinovirus production in organ cultures that had already started to release virus. Five rhinovirus types available for infection of volunteers and six recently obtained clinical isolates were shown to be more sensitive to LY122771-72 in tissue culture than the rhinovirus type 31 used in the organ culture experiments. These results suggest that this potential antiviral drgu should be evaluated in humans.

Potential Use of Antiviral Agents in Polio Eradication

“…Enviroxime is a benzimidazole derivative that inhibits the replication of enteroviruses and rhinoviruses in vitro by targeting the nonstructural protein 3A (19,20). Enviroxime (Table).…”

The Capsid Binder Vapendavir and the Novel Protease Inhibitor SG85 Inhibit Enterovirus 71 Replication

“…Six enterovirus inhibitors were included in this study: (i) the novel 3C protease inhibitor (PI) SG85 (11) and the PI rupintrivir (12); (ii) the host cell-targeting compound enviroxime (13); and (iii) three capsid binding compounds, i.e., pleconaril, pirodavir, and vapendavir (14)(15)(16). Vapendavir is currently in clinical development for the treatment or prophylaxis of rhinovirus infections in patients at risk of rhinovirus-mediated exacerbation of their underlying respiratory disease(s) (NCT01175226).…”

Antirhinovirus activity of purine nucleoside analogs

“…The search for effective antirhinovirus agents has yielded a wealth of compounds belonging to widely varying chemical classes: thiosemicarbazones (20), isoquinolines (35,43), triazinoindoles (27), guanidines (5), benzoates (30), furanyls (2), benzimidazoles (12), thiourea (18), diketones (14,16,17), flavans (3,32), flavones (25), chalcones (24), nitrobenzenes (34,41), and isoxazoles (15,31). The most recently developed antirhinovirus compounds (3,15,24,31) reach their MICs within the range of 0.001 to 0.01 ,ug/ml.…”